Keywords: meiji, seika, launches, laserphyrin, 100mg, early-stage, lung
Meiji Seika launches Laserphyrin 100mg for early-stage lung cancer treatment
Article | 12 July 2004
Japan's Meiji Seika has launched Laserphyrin 100mg (talaporfin sodium)for injection, a photosensitizer for photodynamic therapy in early-stage lung cancer, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
